U.S. full-market release of Bolt PFA catheter and continued international rollout of Tactiflex Duo are expected to accelerate EP growth and share recapture in the second half.
Abbott expects to launch coronary IVL, Amulet 360, Libre Duo and U.S. Tactiflex Duo PFA at a steady cadence over the next 12 months.
Libre Duo, the dual glucose-ketone sensor, will begin international rollout in the fall and enter the U.S. after FDA approval.
Abbott is planning a fifth CGM manufacturing facility, likely a billion-dollar investment, as it prepares for future capacity needs.
Exact Sciences is expected to add about $3 billion of incremental 2026 sales and accelerate Abbott's long-term growth in cancer diagnostics.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Abbott Laboratories and 4,900+ companies.